Compare MSBI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | IVVD |
|---|---|---|
| Founded | 1881 | 2020 |
| Country | United States | United States |
| Employees | 861 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.1M | 437.1M |
| IPO Year | N/A | 2021 |
| Metric | MSBI | IVVD |
|---|---|---|
| Price | $26.49 | $1.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $24.33 | $8.75 |
| AVG Volume (30 Days) | 144.4K | ★ 2.6M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $18.41 | $61.57 |
| Revenue Next Year | $2.07 | $41.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $14.24 | $0.49 |
| 52 Week High | $26.61 | $3.07 |
| Indicator | MSBI | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 73.53 | 49.15 |
| Support Level | $20.47 | $1.41 |
| Resistance Level | N/A | $2.00 |
| Average True Range (ATR) | 0.76 | 0.10 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 95.41 | 39.10 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.